A new study published in Nature Genetics suggests there may be new ways for personalized and precise treatment of acute myeloid leukemia (AML) that could increase the chances of survival in patients with this aggressive cancer of the white blood cells.
A new study published in Nature Genetics suggests there may be new ways for personalized and precise treatment of acute myeloid leukemia (AML) that could increase the chances of survival in patients with this aggressive cancer of the white blood cells.
AML is made up of several groups of cells with different combinations of mutations, some of which are so aggressive they allow the cancer cells to survive after treatment. The different types of genetic alterations affect signaling pathways as well as transcriptional factors and epigenetic regulators. Mutations target genes that encode either master regulators that control cell identity or factors transmitting signals through the cell. Thus, in AML the normal process of turning genes on or off is dysfunctional.
When mutations occur, the cells retreat from their normal developmental program and speed out of control, Constanz Bonifer, PhD, the senior study author, explained in an associated press release. “Crucially, AML cells from patients with the same type of mutations always take the same route when they head off in the wrong direction.”
The researchers conducted a comprehensive global analysis of cis-regulatory element activity and interaction, transcription factor occupancy, and gene expression patterns in purified leukemic blast cells. They focused on specific subgroups of patients diagnosed with AML whose cells carry mutations in genes encoding transcription factors RUNX1 and CEBPα, signaling molecules FTL3-ITD, and RAS, and the nuclear protein NPM1.
Their analysis uncovered the basic mechanisms that regulate the production of these abnormal cells and identified the main trigger points and critical mutations in which affect other genes that control the cells’ identity and behavior. Each mutant regulator establishes a specific transcriptional and signaling network unrelated to that seen in normal cells, sustaining the expression of unique sets of genes required for AML growth and maintenance. Induced and aberrantly expressed transcription factors are not bystanders, the researchers conclude, but are important for network maintenance and leukemic growth. The AP-1 transcription factor family in particular—which plays an important role in many types of tumors—was found to play a major role in AML.
Bonifer explained that the mutations are often present before treatment, “but we have never previously been able to identify them when a patient is first diagnosed with AML—meaning that the cancer can later return as a different disease which is often more aggressive.” The new research makes it possible to identify these cells at diagnosis, allowing treatment with the right drug combination.
Peter Cockerill, PhD, the other senior author on the study, noted that patients with AML are already being tested for the many different mutations that cause AML, but now researchers know which genes are the most important for each type of AML. “This means that personalized medicine will one day become a reality for blood cell cancers, which will see a different drug being given to treat each form of AML, creating personalized treatment for each cancer patient depending on the mutation that has caused their disease.”
This research was funded by Bloodwise, a blood cancer research charity based in the United Kingdom.
Reference
Assi SA, Imperato MR, Coleman DJL, et al. Subtype-specific regulatory network rewiring in acute myeloid leukemia [published online November 12, 2018]. Nat Genetics. doi: 10.1038/s41588-018-0270-1.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More